← board
KZIA
distress 4/10 · elevated risk$14.570%today-7% from 52w high
Revenue
pre-revenue
Liquidity
$69M
Runway
5.2 yrs
Shares 1y
+1572%
Price & events
+108.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.2%
1D
+11.1%
1W
-0.8%
1M
+23.3%
3M
+94.0%
6M
+41.7%
1Y
-23.3%
2Y
-97.0%
5Y
-96.8%
All
Overview
- Market Cap
- $11.79B
- Volume
- 6.75K
- 52 Week Range
- $5.00 – $15.72
- Total Shares
- 809.42M
- Float Shares
- 8.04M
- Short %
- 5.66%
- % Held by Insiders
- 19.81%
- % Held by Institutions
- 28.75%
- RVOL
- 0.04x
- Beta
- 2.15
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $28 (+90% upside) · 5 analysts
- 2026-07-15BTIGBuy
- 2026-07-01BTIGBuy
- 2026-06-11Lake StreetBuy
- 2026-04-15Laidlaw & Co.Buy
- 2026-01-28HC Wainwright & Co.Buy
- 2025-12-12HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.